New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer’s disease (AD). The data was featured during the “Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations” Developing Topics Session #1-32-FRS-C. AD is a chronic, progressive...

The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1 EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Data presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, CanadaCOPENHAGEN, Denmark, July 12, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1. Data is presented today in a poster session at the International Herpesvirus Workshop (IHW)...

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing HMB-003 program announced as non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented...

PASCAGOULA, Miss., July 11, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened the future USS George M. Neal (DDG 131), the fourth Flight III Arleigh Burke-class destroyer to be built at the company’s Ingalls Shipbuilding division. The ship is named for Aviation Machinist’s Mate Third Class George M. Neal, a Korean War veteran and Navy Cross recipient. In 1951, Neal’s helicopter crashed during a rescue attempt in the North Korean mountains. He evaded enemy forces for nine days before being captured and held as a prisoner of war for two and a half years. He was released and returned to the United States in 1952 along with more than 320 fellow prisoners of war. Performing the duties of the under secretary of the Navy, William Toti delivered the keynote address. “The future USS George M. Neal honors a legacy of extraordinary courage...

TORONTO, July 11, 2026 (GLOBE NEWSWIRE) — Discovery Mining Ltd. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced that the Company will release its financial and operating results for the second quarter of 2026 prior to the market open on Thursday, August 13, 2026, Eastern Time (“ET”). The Company will then host a conference call to review the results at 10:00 am ET the same day. Those wishing to join the call can do so using the telephone numbers listed below. The call will also be webcast and available on the Company’s website at www.dsvmining.com. Details Date: Thursday, August 13, 2026Time: 10:00 am ETConference ID: 976047005Dial-in Numbers:  Canada Local: +1 365-657-4084  Canada Toll Free: +1 833-769-6440   USA Toll Free: +1 833-461-5787   All other dial-in numbers: https://help.events.q4inc.com/eahc/international-dial-in-numbers Webcast...

Banzai (Nasdaq: BNZI) commences an underwritten public offering of Class A common stock; Aegis Capital Corp. is sole book-running manager SEATTLE, July 10, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has commenced an underwritten public offering of its Class A common stock (or pre-funded warrants to purchase shares of Class A common stock in lieu thereof). All of the securities in the proposed offering are being offered by Banzai. The aggregate offering amount of the securities issued in the proposed offering, including any securities issued pursuant to an underwriter’s option, approximately $1 million, which is the maximum market value of securities that...

Vancouver, BC, July 10, 2026 (GLOBE NEWSWIRE) — FOBI AI Inc. (FOBI:TSXV) (Pink:FOBIF) (“Fobi” or the “Company”), a company that harnesses AI and data intelligence to enable digital transformation, is pleased to announce that the British Columbia Securities Commission, as principal regulator of the Company, has issued a full revocation (the “Revocation”) of the failure-to-file cease trade order previously issued against the Company on November 1, 2024 (the “FFCTO”). The FFCTO was issued against the Company for failing to file its annual audited financial statements, related management discussion and analysis (“MD&A”), and certifications for the financial year ended June 30, 2024 (together, the “2024 Annual Filings”). During the period when the FFCTO was in effect, interim financial statements, MD&A, and accompanying CEO...

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) — Burtech Acquisition Corp II (the “Company”), a special purpose acquisition company formed as a Cayman Islands exempted company, today announced that commencing July 14, 2026, holders of the units sold in the Company’s initial public offering completed on May 21, 2026, may elect to separately trade the Class A ordinary shares of the Company and the warrants included in such units on the Nasdaq Global Market tier of  The Nasdaq Stock Market LLC (“Nasdaq”). Each unit consists of one Class A ordinary share of the Company, $0.0001 par value per share,  and one redeemable warrant, each warrant entitling the holder to purchase one Class A ordinary share upon exercise, at a price of $11.50 per share. The Class A ordinary shares and warrants that are separated will trade on Nasdaq under the symbols...

Not for Distribution to U.S. Newswire Services or for Dissemination in the United States of America. TORONTO, July 10, 2026 (GLOBE NEWSWIRE) — Picton Mahoney Asset Management (“PICTON Investments”) today announced that SMA Capital LLC (“SMA Capital”) has been appointed as sub-advisor for the PICTON Market Neutral Equity Alternative Fund and the PICTON Multi-Strategy Alpha Alternative Fund (collectively, the “Funds”), effective July 10, 2026. SMA Capital is an alternative asset management firm that operates a platform of single-manager hedge fund strategies. Established in January 2025, the firm manages a suite of specialized long/short equity strategies across a range of sectors and geographies, including Industrials, Consumer, Asia Technology, Capital Markets, Healthcare and Latin American Equities. SMA Capital manages investment...